These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17470765)

  • 1. Selecting promising ALS therapies in clinical trials.
    Glass JD; Benatar M; Polak M
    Neurology; 2007 May; 68(18):1545-6; author reply 1546. PubMed ID: 17470765
    [No Abstract]   [Full Text] [Related]  

  • 2. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop.
    Ludolph AC; Bendotti C; Blaugrund E; Hengerer B; Löffler JP; Martin J; Meininger V; Meyer T; Moussaoui S; Robberecht W; Scott S; Silani V; Van Den Berg LH;
    Amyotroph Lateral Scler; 2007 Aug; 8(4):217-23. PubMed ID: 17653919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic trials in ALS.
    Bradley W
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Apr; 4(1):6-7. PubMed ID: 12745610
    [No Abstract]   [Full Text] [Related]  

  • 5. [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine].
    Gámez J
    Neurologia; 2008 Oct; 23(8):484-93. PubMed ID: 18802797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New ideas for therapy in ALS: critical considerations.
    Beghi E; Bendotti C; Mennini T
    Amyotroph Lateral Scler; 2006 Jun; 7(2):126-7; discussion 127. PubMed ID: 16753979
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapy development for ALS: lessons learned and path forward.
    Lanka V; Cudkowicz M
    Amyotroph Lateral Scler; 2008 Jun; 9(3):131-40. PubMed ID: 18574756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of amyotrophic lateral sclerosis - what is the next step?
    Ludolph AC
    J Neurol; 2000 Dec; 247 Suppl 6():VI/13-8. PubMed ID: 19714403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is next in ALS clinical trials?
    Sorenson EJ
    Neurology; 2007 Aug; 69(8):719-20. PubMed ID: 17709702
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroprotective agents for clinical trials in ALS: systematic assessment.
    Burke WJ
    Neurology; 2007 Feb; 68(9):709; author reply 710. PubMed ID: 17325287
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuroprotective agents for clinical trials in ALS: a systematic assessment.
    Traynor BJ; Bruijn L; Conwit R; Beal F; O'Neill G; Fagan SC; Cudkowicz ME
    Neurology; 2006 Jul; 67(1):20-7. PubMed ID: 16832072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyotrophic lateral sclerosis--a new role for old drugs.
    Brown RH
    N Engl J Med; 2005 Mar; 352(13):1376-8. PubMed ID: 15800236
    [No Abstract]   [Full Text] [Related]  

  • 14. Preclinical studies: how much can we rely on?
    Rothstein JD
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():22-5. PubMed ID: 15512864
    [No Abstract]   [Full Text] [Related]  

  • 15. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials.
    Rothstein JD
    Ann Neurol; 2003 Apr; 53(4):423-6. PubMed ID: 12666108
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future.
    Choudry RB; Cudkowicz ME
    J Clin Pharmacol; 2005 Dec; 45(12):1334-44. PubMed ID: 16291708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 18. Neuroscience: Standard model.
    Schnabel J
    Nature; 2008 Aug; 454(7205):682-5. PubMed ID: 18685674
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical development of levetiracetam for amyotrophic lateral sclerosis.
    Davies SL; Moral MA
    Drug News Perspect; 2006 Nov; 19(9):572-3. PubMed ID: 17220961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.
    Malta E
    Adv Neurol; 1995; 68():263-9; discussion 271-5. PubMed ID: 8787239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.